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ABSTRACT – Cholinergic urticaria is a relatively common condition defined by itching, redness and whealing induced by exercise and passive 
warming. In turn, acquired idiopathic generalized anhidrosis is a rare disorder of unknown pathogenesis, characterized by an impairment in 
total body sweating despite exposure to heat or exercise. We report two cases of this extremely rare association of cholinergic urticaria and ac-
quired generalized hypohidrosis, and briefly review current knowledge with regard to classification, ethiopathogenesis and therapeutic options. 
KEYWORDS – Hypohidrosis/etiology; Urticaria/complications
RESUMO – A urticária colinérgica é uma patologia relativamente comum definida por máculo-pápulas eritematosas e pruriginosas induzidas 
por aumento da temperatura corporal, passivo ou induzido por exercício físico. Pelo contrário, a anidrose generalizada idiopática adquirida é 
uma doença rara de patogénese desconhecida, caraterizada por um comprometimento da capacidade de sudação, apesar da exposição a calor 
ou exercício. Descrevem-se dois casos desta associação extremamente rara de urticária colinérgica e hipohidrose generalizada adquirida, e 
procede-se a uma breve revisão do conhecimento atual no que respeita à classificação, etiopatogenia e opções terapêuticas. 
PALAVRAS-CHAVE – Hipohidrose/etiologia; Urticária/complicações.
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INTRODUCTION
Cholinergic urticaria (CU) is a type of chronic inducible urticaria 
clinically characterized by pinpoint-sized, highly pruritic wheals with 
surrounding erythema. The wheals are typically provoked by stimulus 
such as physical exercise, warmth, intake of spicy foods and emotio-
nal distress, which increases the body core temperature and promotes 
sweating.1 The symptoms usually subside within one hour, however, 
most patients with CU complain of a stinging or tingling pain and/or 
itching at the onset of symptoms, which appear to highly disrupt their 
quality of life.2 The diagnosis of CU is generally straightforward due 
to its characteristic clinical presentation. However, the underlying pa-
thological mechanism is still not completely understood. CU is rarely 
accompanied by acquired anhidrosis and/or hypohidrosis, suggesting 
that sweat itself is not essential for the development of CU. Almost all 
patients with CU who develop acquired anhidrosis and/or hypohidro-
sis are assumed to have acquired idiopathic generalized anhidrosis.3
Acquired idiopathic generalized anhidrosis (AIGA) is a rare di-
sorder characterized by inadequate sweating in response to heat, 
in the absence of apparent causative skin, metabolic, or neurologi-
cal etiologies. This disorder affects predominantly young males and 
is often complicated by pain and/or paresthesia, severely disturbing 
quality of life.4 Psychogenic sweating is usually preserved. Exposure 
of these patients to high temperatures often results in heat stroke, 
with symptoms such as general malaise, hyperthermia, dizziness, 
palpitations, fainting and ultimately loss of consciousness due to the 
dysregulation of body temperature.5
We report two cases of CU associated with acquired generalized 
hypohidrosis, both refractory to multiple treatments and with severe 
disruption of quality of life.
Case Reports
Case 1
A previously healthy young male presented in early 2020 a 1-year 
history of pinpoint-sized, pruritic wheals, initially circumscribed to the 
trunk, and later also affecting the limbs. They were associated with 
tingling pain and hyperthermia, and followed physical exercise, ex-
posure to hot weather and emotional stress. He took cold showers 
to alleviate symptoms. His growth and development were normal. 
Sweating was normal till the present condition. In fact, shortly before 
the onset of the skin lesions, he noticed generalized anhidrosis and 
intolerance of hot environments, especially during summer. There 
were no episodes suggestive of heat stroke. He had no personal his-
tory of atopic diathesis. His familial history was unremarkable.
The following laboratory studies were all within the normal range: 
full blood count, urinalysis, serum protein electrophoresis, blood urea 
nitrogen, creatinine, C-reactive protein, fasting blood glucose, liver 
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enzymes, potassium, sodium and chloride ions and thyroid function. 
Anti-nuclear antibodies were positive (1:160 titer); other autoantibo-
dies were negative. The Helicobacter pylori breath test was negative. 
Serologies to cytomegalovirus, Epstein-Barr virus and syphilis were 
also negative. Abdominal ultrasonography was normal. He visited 
a rheumatologist that did not find any clinical evidence of immune 
mediated disease.
The patient had been treated with second generation H1-antihis-
tamines, with little benefit. Prednisolone was later introduced (20 mg 
initially, with tapering dosages) along with second generation H1-
-antihistamines up-dosing and montelukast, with limited effectiveness 
on both the anhidrosis and CU.
Case 2
A previously healthy young male presented in 2018 a 6-month 
history of pinpoint-sized, pruritic wheals, associated with stinging 
pain. The wheals appeared on the trunk and limbs following an in-
crease in body core temperature, either by exposure to hot weather 
or physical exercise. He had a wet cloth with him at all times, that he 
applied on the skin to alleviate symptoms. He was unable to go to 
school, since the classrooms had no air conditioning. In summer he 
was confined to his home. His growth and development were normal. 
In one of the consultations his father mentioned that he no longer 
sweated. When asked, he had episodes suggestive of heat stroke. 
There was no personal or familial history of atopic diathesis. The 
pin-point lesions were observed whenever the air conditioning was 
turned off in the office.
The following laboratory studies were all within the normal range: 
full blood count, urinalysis, serum protein electrophoresis, blood urea 
nitrogen, creatinine, C-reactive protein, fasting blood glucose, liver 
enzymes, tryptase, immunoglobulins, potassium, sodium and chlo-
ride ions and thyroid function. Autoantibodies were negative. A skin 
biopsy from the axilla was performed, which showed no evidence of 
sweat gland atrophy, occlusion of the ducts or periglandular inflam-
matory infiltration.
The patient had been treated with second generation H1-antihis-
tamines, with little benefit. Prednisolone was later introduced (up to 
40 mg daily) along with second generation H1-antihistamines up-do-
sing, montelukast, ranitidine, propranolol and scopolamine butylbro-
mide, with limited effectiveness on both the anhidrosis and the CU. 
Omalizumab treatment was initiated (300 mg with 4-week intervals), 
but after 5 months without clinical response it was discontinued. At 
this point, an intravenous high-dose (methylprednisolone 500 mg for 
3 days) steroid pulse therapy was tried followed by oral prednisolone 
at 40 mg/day, but failed to produce any improvement in symptoms. 
A trial of oral cyclosporine was also attempted, again without any 
satisfactory results.
DISCUSSION
Several research groups have proposed four subtypes of CU 
based on the pathogenesis and clinical characteristics of this condi-
tion: (a) sweat allergy-type, (b) follicular-type, (c) CU with angioede-
ma and/or anaphylaxis, and (d) CU with acquired anhidrosis and/
or hypohidrosis.4
The conventional sweat-hypersensitivity type is characterized by 
non-follicular wheals, development of satellite wheals following local 
acetylcholine injection, a positive autologous sweat skin test result 
and a negative autologous serum skin test result.6
The follicular type is characterized by pinpoint wheals coincident 
with follicles, no development of satellite wheals following local ace-
tylcholine injection, a positive autologous serum skin test result and 
lack of sweat allergy.3
CU with angioedema and/or anaphylaxis appears to be close-
ly related to atopic diathesis, female gender and high prevalence 
of sweat allergy. Wheals in these patients often appear in eczema-
tous lesions consistent with atopic dermatitis. These patients respond 
poorly to H1-antihistamines.7,8
It seems to be especially important to differentiate the subtypes 
described above from subtype (d), particularly in terms of the swea-
ting function, since increasing reports suggest that the therapeutic 
approach should be different.3
As previously stated, it is assumed that almost all patients with CU 
who develop acquired anhidrosis and/or hypohidrosis have AIGA. 
No epidemiological data on AIGA has been published to date. Ne-
vertheless, it is thought to be rare, as less than 200 cases have been 
reported in literature.9 Patients with AIGA may be misdiagnosed as 
having other conditions since it is still an underrecognized disease.
The etiology and pathophysiology of AIGA seem to be heteroge-
neous. The most consensual mechanisms are (a) dysfunction or dege-
neration of cholinergic sympathetic nerve fibers involved in sweating 
(sudomotor neuropathy), (b) dysfunction of acetylcholine receptors 
and/or cholinergic signals, and (c) sweat gland failure, namely poral 
occlusion.9 In the first two mechanisms, the anhidrosis results in his-
tological degeneration; in the latter, the destruction of sweat glands 
results in anhidrosis. These conditions cannot be differentiated at pre-
sent, but the latter has a more prolonged clinical course.5
Sudomotor neuropathy is believed to affect only sudomotor func-
tion without causing any other types of neuropathy. Possible sites of 
dysfunction include the hypothalamus, the medulla oblongata/spinal 
cord, and the preganglionic and postganglionic sympathetic efferent 
fibers.10
Decreased expression of the muscarinic acetylcholine M3 re-
ceptor (CHRM3) in the sweat glands has been observed in patients 
with AIGA, as well as reduced expression of acetylcholine esterase.11 
These findings suggest that there is an excess of acetylcholine that 
cannot interact with cholinergic receptors, resulting in the stimulation 
of sensory nerve terminals, which produces pain and acts on CHRM3 
in mast cells around the sweat glands, causing wheals. The involve-
ment of autoantibodies to the muscarinic acetylcholine M3 receptor 
in sweat glands has been proposed as the underlying mechanism.12
Anhidrosis in sweat gland failure is a result of primary immunolo-
gical destruction of sweat glands, which may comprise many hetero-
geneous pathological conditions, poral occlusion being one of them.5 
Kobayashi et al reported two patients whose biopsies showed occlu-
sion of the superficial acrosyringium.13 They proposed that the oc-
clusion and subsequent leakage of sweat from the sweat ducts were 
responsible for the development of the disease, since sweat contains 
several inflammatory enzymes and cytokines which can induce local 
inflammation.
Diagnostic criteria for AIGA have been published by Munetsugu 
et al.5 They establish the diagnosis of AIGA when anhidrotic or hypo-
hidrotic areas affect 25% or more of the entire body, the lesions are 
widely distributed in a non-segmental spinal pattern, and no other 
autonomic or neurological symptoms are observed.
The anhidrotic or hypohidrotic areas can be detected by the ther-
moregulatory sweat test or by thermography.5 The thermoregulatory 
sweat test based on the Minor method using the iodine-starch reac-
tion is the most commonly performed and easy to interpret, since the 
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areas that do not turn black are the anhidrotic or hypohidrotic ones. 
When thermography is performed in combination with the thermore-
gulatory sweat test, areas of increased body temperature are found 
to correspond to anhidrotic areas.5 Both these tests are not widely 
available.
In recent years, some authors have proposed that the therapeutic 
approach to CU should be distinct depending on whether there is 
sweating dysfunction or not.3 Pharmacological therapy and avoidan-
ce of causative factors are standard approaches for CU.14
Second generation H1-antihistamines are first-line therapy for 
patients with CU, but their efficacy is often limited, either with stan-
dard or increasing doses.15 The addition of an H2-receptor antago-
nist has been reported to be effective in patients with refractory CU 
unresponsive to up-dosing of an H1-receptor antagonist.2 Other stu-
dies have demonstrated the efficacy of scopolamine butylbromide,16 
propranolol and montelukast.17 Omalizumab has been reported to 
be effective for severe CU, although treatment failure has also been 
reported.18
High doses of danazol (600 mg daily) have been reported to be 
effective. However, the side-effect profile of danazol restricts its use, 
and dosing should be minimized.14
Topical application of keratolytic agents is reportedly effective 
in treating hypohidrotic CU associated with the occlusion of sweat 
ducts.19
Despite insufficient level of evidence, systemic administration of 
corticosteroids is recommended for management of early onset AIGA 
and concurrent cholinergic urticaria, on the basis of findings pre-
sented in numerous case reports.4,5,20 However, patients with delayed 
treatment initiation or degeneration of sweat gland tissue may res-
pond poorly.5 The most common forms of steroid therapy include ste-
roid pulse therapy alone (1-2 courses of a 3-day intravenous infusion 
of methylprednisolone at a dose of 500-1000 mg/day), steroid pulse 
therapy followed by oral prednisolone at 30-60 mg/day, and oral 
prednisolone at 30-60 mg/day followed by dose tapering. Neverthe-
less, the evidence regarding appropriate doses and administration 
routes is still not very robust. A trial of oral immunosuppressants may 
be considered in patients who do not respond to steroid therapy.5
Desensitization protocols involving regular physical exercise and/
or bathing or treatment with autologous sweat in patients with sweat 
allergy-type CU have been described.13,21,22 Very recently, Minowa et 
al23 published a retrospective medical record review of 27 patients 
where they found that regular sweating activities, alone or with se-
cond generation antihistamines or steroid pulse, provided symptom 
relief in 92% of the patients, and the effects of regular sweating acti-
vities were rapidly established (median time of 1.5 months).
Our first patient was diagnosed very recently and is still going 
through the therapeutic steps proposed by the EAACI consensus re-
commendations.14
In our second patient, since the EAACI treatment guidelines pro-
ved ineffective, steroid pulse therapy was attempted. It also failed to 
produce results, and we can speculate that one possible reason for 
that was delayed treatment initiation. The good results reported by 
Minowa et al23 in their desensitization protocol gives a new hope and 
will be considered for this patient in the near future.
Munetsugu et al5 have proposed an algorithm for the treatment of 
AIGA. After the diagnosis, the disease should be adequately explained 
to patients, so that they understand the high risk of heatstroke due to 
the thermoregulatory disorder associated with decreased sweating. As 
part of lifestyle guidance, patients should be instructed on techniques 
for preventing heatstroke. When AIGA is severe (area of anhidrotic/
hypohidrotic lesions >75% and area of painful skin or wheals >75%), 
steroid therapy should be considered (recommendation grade: C1). 
Steroid therapy should also be considered for patients with pain or 
symptoms of heatstroke that disrupt daily life or work.5
CONCLUSION 
The available evidence suggests that various pathological me-
chanisms contribute to the development of AIGA. Depending on the 
different etiologies, the clinical courses appear to be distinct. Howe-
ver, at present it is not possible to clarify the specific underlying me-
chanism responsible for each AIGA case.
CU associated with acquired generalized hypohidrosis is an ack-
nowledged clinical entity, although still underrecognized, underre-
ported and, unfortunately, often refractory to the available therapies. 
Systemic corticosteroids are unquestionably the most effective thera-
peutic option. However, many patients are resistant to corticosteroi-
ds and/or experience recurrence. It is imperative to develop novel 
alternative therapies, as these patients suffer great deterioration in 
quality of life.
To our knowledge, these are the only cases of cholinergic urtica-
ria associated with acquired generalized hypohidrosis reported in our 
country. Furthermore, we did not find in PubMed any other published 
reports of similar cases in Europe.
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